PDCD1 and colorectal carcinoma: Similarly, a Chinese observational cohort reported a pCR of 47.6% after a single-agent anti-programmed cell death protein 1 (anti-PD-1) therapy, and the IMHOTEP trial reported a pCR of 54.4% with P in its CRC cohort, which were lower than in previous clinical trials.19